HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Sulfate-Free To Anti-Shampoo: Natural Movement In Hair Care

This article was originally published in The Rose Sheet

Executive Summary

Trend for “free of” products in hair care is growing, as consumers demand gentle formulas created without ingredients that dry out hair and scalp, says global ingredient distributor Univar Inc. At extreme end of trend, some consumers are nixing shampoo altogether.

You may also be interested in...



In Brief: Mintel Forecasts Rise In Multifunctionals; Pureology Rides The Wave

More multifunctional products will be entering the market in 2014, building on the success of BB and CC creams, Mintel predicts; Pureology is on trend with a new “multitasking hair beautifier.” More news in brief.

J&J To Remove Formaldehyde, Other Concerns From Personal-Care Items

In response to consumer demand, J&J will remove controversial ingredients from both baby and adult brands, including Neutrogena, Aveeno, Lubriderm and Clean & Clear.

FDA’s OTC Monograph User Fees Are Existential Threat To Small Contract Manufacturers, Cosmetics Brands

OMUFA reauthorization should include small business considerations for the US FDA’s OTC Monograph Drug User Fee Program, which established in 2020 a ‘one-size-fits-all’ facility and monograph order request user fee system which could lead to more contract manufacturer exits, a manufacturing bottleneck for OTC cosmetic products, and fewer product choices, says IBA.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel